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Alprazolam use and related harm among opioid substitution treatment clients 12 months follow up after regulatory rescheduling
Abstract
Background Alprazolam, has been associated with disproportionate harms compared to other
benzodiazepines, especially among people in opioid substitution treatment (OST). We examine the effect
of the rescheduling of alprazolam in Australia, from Schedule 4 to Schedule 8 in February 2014 amongst a
high-risk population of clients in OST. Methods OST participants who reported recent (last month)
alprazolam use were recruited from three Sydney clinics. Participants (n = 57) were interviewed
immediately prior to rescheduling and again three months and 12 months after rescheduling. We
examined self-reported patterns of drug use, drug availability, mental and physical health. A linear mixed
models approach was used to analyse changes in alprazolam and other benzodiazepine use. Results
Mean days of alprazolam use in the past 28 days decreased from 13.7 to 7.1 days, and mean weekly
alprazolam dose decreased from 15.1 mg to 6.1 mg at 12 months follow-up (p = 0.001). Total weekly
benzodiazepine use also reduced from a mean of 222 mg diazepam equivalent to 157 mg (p = 0.044).
Other substance use did not change significantly. Reported mode of cost price of street alprazolam
doubled from $5 to $10 over the 12-month period. Conclusion Alprazolam rescheduling resulted in an
overall reduction in alprazolam and total benzodiazepine use, without substitution with other drugs, in the
short term. Unintended harms were not observed. Rescheduling appears to have been effective in
reducing alprazolam use in this high-risk population.
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ALPRAZOLAM USE AND RELATED HARM AMONG OPIOID SUBSTITUTION TREATMENT
CLIENTS - 12 MONTHS FOLLOW UP AFTER REGULATORY RESCHEDULING

Background:
Alprazolam, has been associated with disproportionate harms compared to other benzodiazepines,
especially among people in opioid substitution treatment (OST). We examine the effect of the rescheduling
of alprazolam in Australia, from Schedule 4 to Schedule 8 in February 2014 amongst a high-risk population
of clients in OST.
Methods:
OST participants who reported recent (last month) alprazolam use were recruited from three Sydney clinics.
Participants (n=57) were interviewed immediately prior to rescheduling and again three months and 12
months after rescheduling. We examined self-reported patterns of drug use, drug availability, mental and
physical health. A linear mixed models approach was used to analyse changes in alprazolam and other
benzodiazepine use.
Results:
Mean days of alprazolam use in the past 28 days decreased from 13.7 to 7.1 days, and mean weekly
alprazolam dose decreased from 15.1 mg to 6.1 mg at 12 months follow-up (p=0.001). Total weekly
benzodiazepine use also reduced from a mean of 222 mg diazepam equivalent to 157 mg (p=0.044). Other
substance use did not change significantly. Reported mode of cost price of street alprazolam doubled from
$5 to $10 over the 12 month period.
Conclusion:
Alprazolam rescheduling resulted in an overall reduction in alprazolam and total benzodiazepine use, without
substitution with other drugs, in the short term. Unintended harms were not observed. Rescheduling appears
to have been effective in reducing alprazolam use in this high-risk population.
Keywords: alprazolam, opioid substitution treatment, prescription drug misuse, benzodiazepines
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Background

Benzodiazepine misuse among opioid-substitution treatment (OST) clients is both highly prevalent (Chen et
al., 2011; Darke et al., 2010; Iguchi, Handelsman, Bickel, & Griffiths, 1993; Lavie, Fatseas, Denis, &
Auriacombe, 2009; Nielsen, Dietze, Lee, Dunlop, & Taylor, 2007; Peles, Schreiber, & Adelson, 2010) and
associated with a number of adverse outcomes (Ashton, 2005; Lintzeris & Nielsen, 2010). These include
reduced likelihood of opioid abstinence (Kamal et al., 2007), early withdrawal from treatment (Meiler, Mino,
Chatton, & Broers, 2005; Peles et al., 2010), increased use of other psychotropic drugs and greater levels of
anxiety and depression (Lavie et al., 2009), participation in crime and injecting-related risks (Darke, Hall,
Ross, & Wodak, 1992). Benzodiazepine misuse among OST clients presents a serious public health risk as
these individuals are at increased risk for multiple drug overdoses (Chen et al., 2011). Internationally,
benzodiazepines are commonly implicated in opioid-related mortality (Park, Saitz, Ganoczy, Ilgen, &
Bohnert, 2015), with alprazolam the most commonly prescribed benzodiazepine in the US (IMS Institute for
Healthcare Informatics, 2015) and most frequently implicated benzodiazepine in emergency department
drug-related presentations (Substance Abuse and Mental Health Services Administration, 2013).

In the general population in Australia, benzodiazepine use has been gradually decreasing since 1992, with
the exception of alprazolam where an 8-plus fold increase in alprazolam use was observed between 1992
and 2011 (Islam, Conigrave, Day, Nguyen, & Haber, 2014). Whilst not all OST clients experience harms or
dependence on benzodiazepines (Lintzeris & Nielsen, 2010), approximately one third (38%) of clients at two
public OST services in Sydney self-report benzodiazepine use in the past 28 days (Deacon et al., 2014).
Alprazolam has been thought to be associated with a disproportionate amount of harm compared to other
benzodiazepines (Horyniak, Reddel, Quinn, & Dietze, 2012; Moylan, Giorlando, Nordfjaern, & Berk, 2012;
Moylan et al., 2011). Alprazolam is considered a high potency benzodiazepine compared to other
benzodiazepines (Truven Health Analytics). Due to its short elimination half-life and high potency it has been
identified to be particularly problematic with respect to dependence liability and withdrawal seizures (Wolf &
Griffiths, 1991). Among patients on methadone programs, alprazolam has been associated with aggression
and problematic potentiation of both drugs (K. Jones, Nielsen, Bruno, Frei, & Lubman, 2011). There have
been increased alprazolam detections reported with heroin-related overdoses (Rintoul, Dobbin, Nielsen,
Degenhardt, & Drummer, 2013), an overrepresentation of alprazolam in overdose cases (Buykx, Loxley,
Dietze, & Ritter, 2010) and an increased risk of overdose with alprazolam in general (Isbister, O'Regan,
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Sibbritt, & Whyte, 2004).

Driving accidents and seizures are also associated with alprazolam use (Nielsen

et al., 2008).

More stringent regulation is one public health approach in response to concerns about illicit or harmful use of
medicines. A recent example is the rescheduling of hydrocodone, a commonly misused opioid analgesic in
the US. Compared to the 36 months before rescheduling in October 2014, the number of hydrocodone
prescriptions decreased by 22% and volume of dispensed hydrocodone product decreased by 16% in the
following 12 months (C. M. Jones, Lurie, & Throckmorton, 2016). A modest (4.9%) increase in nonhydrocodone opioid analgesic prescriptions did not substantially offset the drop in hydrocodone. In response
to concerns with alprazolam, increased restrictions around alprazolam supply were introduced in Australia on
1 February 2014, when this medication was re-categorised from Schedule 4 to Schedule 8. With this change
came jurisdictional modifications in storage and prescribing requirements. For example, in NSW doctors
must now obtain a specific authority from Pharmaceutical Services in the Ministry of Health to prescribe
alprazolam for an extended period of time (> two months in New South Wales [NSW]) or prior to prescribing
alprazolam to a drug dependent patient (this includes all OST patients as defined in the NSW Therapeutic
Drugs & Poisons Act ("Poisons and Therapeutic Goods Act 1966 [statute on the internet],")). Reduced
availability is intended to reduce inappropriate use and harms. However, it is unclear as to whether such
regulatory changes are effective in modifying access and use in those individuals at greatest risk of
experiencing harms. Furthermore, restrictions in access to alprazolam could also be associated with
unanticipated harms such as withdrawal syndromes in dependent individuals (presenting with seizures,
panic attacks, anxiety, delirium) or increases in the use of other (and potentially more harmful) substances or
routes of administration (e.g. injected opioids).

This study aimed to assess the intended and unintended consequences of rescheduling alprazolam, to
examine the impact of regulatory policy changes in this high-risk population. Drug use and wellbeing were
examined in alprazolam-using OST clients in the periods immediately before, three months and twelve
months after the regulatory changes, using a prospective longitudinal cohort design.
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Methods

Study design
The study used a longitudinal cohort design to examine a range of outcomes in a group of alprazolam using
OST clients immediately before, three months and 12 months after the rescheduling of alprazolam on 1st
February 2014. Participants were recruited from three public specialist OST clinics in Sydney: The Langton
Centre, St George Drug and Alcohol Service (both services of Drug and Alcohol Services, South East
Sydney Local Health District) and Rankin Court (Alcohol and Drug Service, St Vincent’s Hospital),
representing approximately 750 OST clients. Eligible participants were required to have been on OST
(methadone or buprenorphine) at one of the study clinics for at least one month prior to being interviewed
and to have self-reported use of alprazolam at least once in the past month. Exclusion criteria included
severe mental health (e.g. acute psychosis, delirium) and/or severe cognitive deficits preventing informed
consent, an impending custodial sentence or transfer to another service precluding participation in the followup interviews. Participants were required to attend three structured interviews (each approximately two hours
in duration) with an independent researcher: one month before, three months and 12 months following the
rescheduling. The study was advertised with fliers displayed in the clinics, as well as potentially eligible
clients being referred by clinicians. Participants received a $40 supermarket voucher for reimbursement of
time and effort at the conclusion of each interview.

Ethical approval was provided by the South Eastern Sydney Local Health District Human Research Ethics
Committee (HREC/13/POWH/465) with site approval by St Vincent’s Hospital Sydney Human Research
Ethics Committee. It conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004).
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Measures
Baseline demographic data was collected for all participants. Both pre- and post-rescheduling interviews
explored participants’ drug use including a 28-day recall of days of alcohol, illicit and pharmaceutical drug
use, a detailed 7-day history of drug use (including amount used, source (illicit or licit/prescription) and cost
(illicit or licit)) using time-line follow-back techniques, lifetime history of benzodiazepine and other sedative
use and current OST treatment type. Participants were also asked if they had experienced any non-fatal
overdoses in the last three months as a result of their benzodiazepine use. Cognition was measured with the
Montreal Cognitive Assessment (MOCA) (Nasreddine et al., 2005), designed to distinguish participants with
mild cognitive impairment (MOCA score less than 26/30) from those with normal cognition. Mental and
physical health was measured with the SF-36v2 Health Survey (Ware & Sherbourne, 1992), a 36 item
validated scale which measures general physical component scores (PCS) and mental health component
scores (MCS). Normative scores based on US 1998 data are mean 50 and standard deviation 10. The short
version (21 item) of the Depression Anxiety Stress Scales, or DASS, (Lovibond & Lovibond, 1995) was used
to measure depression, anxiety and stress. Cut-off scores out of 21 for severe or very severe depression,
anxiety and/or stress are 11+, 8+ and 13+ respectively. The Insomnia Severity Index, or ISI, (Bastien,
Vallieres, & Morin, 2001) - a 7-item scale with a total score of 28, where a score of 15 or above indicates
clinically significant insomnia - was used to assess sleep.

Benzodiazepine use was reported as (i) mean dose (mg) used in the last seven days and (ii) mean days of
use in the last 28. Standard deviation (SD) was reported for each measure. Where different benzodiazepine
types were combined, quantities consumed were converted into oral diazepam equivalent doses using
available references (National Prescribing Service, 1999; Therapeutic Guidelines Limited, 2013). The
alprazolam equivalent dose used was 0.5mg to 5mg diazepam.
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Analysis
Analysis was conducted in SPSS version 21. Descriptive statistics were used to describe baseline
characteristics of the cohort – current OST treatment, gender, age, employment, homelessness, education,
and mental and physical health. Parametric tests (e.g. means, t-test) were used for normally-distributed data,
and non-parametric tests (e.g. medians, Wilcoxon signed rank test) for skewed data. The characteristics of
participants who were and were not followed up at 12 months were compared.

Linear mixed models were used to model changes in alprazolam and all benzodiazepine use over the three
waves of data collection. A mixed model approach was selected to account for correlation between repeated
measures, allow for both fixed and random effects, and impute missing data. The outcome variables for the
four models were: (i) mean total mgs used in the last seven days and (ii) mean days of use in the last 28 for
alprazolam; and (iii) total diazepam equivalent mgs used in the last seven days and (iv) mean days of use for
all benzodiazepines. For each model, an autoregressive covariance structure was chosen with interview
wave as the repeated measure and participants as the subject grouping. The intercept was included as a
random effect and maximum likelihood estimation was used. Base models were calculated using only
interview wave as a fixed predictive variable. Then other participant characteristics variables expected to
influence benzodiazepine use were included in the model based on forward selection, with Akaike’s
Information Criterion (AIC) used to judge improved model fit. These were recruitment site, age, gender,
cognition (MOCA score), physical health (PCS), depression, anxiety, and stress (using individual DASS
subscale scores), and insomnia (ISI score). Base and best-fit model estimations at each interview wave are
reported for each outcome variable.

Complete case analysis using descriptive statistics was used to explore the use of non-benzodiazepine drug
classes

including

heroin,

pharmaceutical

opioids,

amphetamines,

cocaine,

cannabis,

alcohol,

antidepressants and antipsychotics, as well as overdose reports, over the three waves of data. Data from
those participants who were not interviewed at follow up one and two were not used for this sub-analysis as
descriptive statistics cannot account for missing data.
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Results
Baseline demographics
A flow diagram illustrating the number of participants at each wave is shown in Figure one. From an
estimated pool of 750 OST clients across 3 clinics of which an estimated 285 or 38% (Deacon et al., 2014)
would have used benzodiazepines (not necessarily alprazolam) in the last month, the total number of
participants recruited was 57. Sixty one participants were screened for eligibility, with three of them not
meeting eligibility criteria (no reported alprazolam use in the last 28 days). Of the 58 eligible participants, 57
completed the baseline interview, 48 (84%) completed the three month interview and 35 (61%) completed
the 12-month interview. Of the 22 participants lost to follow-up, 10 remained clients of the OST clinic but
either declined further interview (n=8) or were too unwell (n=2). Demographic, mental and physical health
measures at baseline comparing the 35 participants followed up with the 22 participants lost to follow-up are
presented in Table one.
<Insert Figure one here>
<Insert Table one here>

At baseline, 60% percent of participants were male and their mean age was 44 years. Thirty three percent
had completed high school education, seven percent were currently employed and nine percent were
homeless. Most (82%) were prescribed oral methadone, the remainder sublingual buprenorphine/naloxone.
Participants reported a median of 15 years of regular benzodiazepine use (defined as the number of years
since >one month without using benzodiazepines), ranging from one to 53 years. Twenty eight percent met
the cut-off for normal cognitive functioning (MoCA >26/30). The only significant differences in baseline
characteristics between participants followed up and not followed up at 12 months (Table one), was years of
regular benzodiazepine use (24.5 years use compared to 8.5 for those followed up, p=0.002).

Changes in alprazolam and other benzodiazepine use
After alprazolam, the most frequently used benzodiazepines were, in order, diazepam, clonazepam,
oxazepam, temazepam, nitrazepam and flunitrazepam. One person reported using zolpidem, a Z-hypnotic,
at follow-up. As the effects of zolpidem are broadly similar to benzodiazepines, it was combined with
benzodiazepines.

Proportions

of

participants

using

diazepam (68%), clonazepam (37%),

other

benzodiazepines (19%), and any non-alprazolam benzodiazepines (77%) in the previous 28 days at baseline
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did not change significantly at follow-up. However, alprazolam use did drop from 100% use at baseline to
36/28 (75%) use at three months and 20/45 (67%) use at 12 months follow-up.

<Insert table two here>
Table two presents the four linear mixed models for changes in volume and frequency of alprazolam and all
benzodiazepine use over the three waves of data collection. The base model for Model one (total seven day
alprazolam load) showed a significant (p=0.007) decrease at three months which was maintained (p=0.001)
at 12 months post-rescheduling. After controlling for the covariates that improved model fit (PCS,
depression, stress, ISI), time still remained a significant predictor of use. Alprazolam load decreased from a
mean of 15.1 mg at baseline to 6.1 mg at 12 months follow-up (p=0.001). Similarly, days of alprazolam use
in the previous 28 (Model two, Table two) significantly decreased at both three and 12 months, and nearly
halved from 13.7 days at baseline to 7.1 days at 12 months follow-up (best-fit model controlled for physical
component score, insomnia and anxiety; p=0.001).

There was no significant change in the seven day load of all benzodiazepines (diazepam equivalent) at three
months (Model three: best-fit controlled for physical component score, insomnia and anxiety; p=0.972).
However, at 12 months follow-up load had dropped from 225mg to 151mg (p=0.028). Days of use in the past
28 of all benzodiazepines did not reach significance after controlling for physical component score and
insomnia (Model four; p=0.065).

A sensitivity analysis was carried out (results not presented) to assess the effect of the major nonbenzodiazepine drug use classes (cannabis, alcohol, methamphetamine and heroin) on the four linear mixed
models, but no significant effects on benzodiazepine use was seen.

Changes in other drug use

Data on non-benzodiazepine drug use among participants are presented in Table three. Considering the 35
participants who were followed up at both three and 12 months post-rescheduling, a majority of participants
(60%) had used cannabis in the previous 28 days at baseline, followed by alcohol (51%), heroin (49%),
amphetamines (34%), pharmaceutical opioids (20%) and cocaine (14%; table 3). One-third (31%) of
participants used anti-depressants, and 14% anti-psychotics, mostly licit (prescribed) use. There were no

9

significant changes in proportions used over the three waves. Days of use in the last 28 (calculated only for
those participants who used each drug at each time point) are also reported for the three waves. No
significant changes in frequency of use were seen.

<Insert Table three here>

Changes in mental and physical health
Data on mental and physical health of participants are reported in Table four. At baseline, most (71%) fell
below the cutoff for normal cognition. Most (71%) also fell below the Australian population norm for the
physical (73%) and mental (91%) component scores of the SF36. Approximately half scored above the
severe threshold for depression (54%), anxiety (69%), and stress (49%). Insomnia was also clinically
significant in 51% of participants. There were no significant changes in mental or physical health between
baseline and follow up two, except for a decrease in the proportion with clinically significant insomnia.

Three, zero and two participants reported overdose due to benzodiazepine use in the last 3 months at
baseline, follow up 1 and follow up 2 respectively. Being a relatively low frequency event, with the sample
size the study was not powered to detect a difference on this measure.

<insert table Four here>
Alprazolam availability and price
At baseline, most of the sample reported using only illicit alprazolam (n=45, 79%), defined as any source that
was not a participant’s own prescription (e.g. supplier, other person’s prescribed medication).

Three

participants (five percent) reported using prescribed alprazolam only, and nine (16%) reported a combination
of prescription and illicit sources. At 12 months follow-up, a similar proportion (n=20/28, 80%) reported using
only illicit alprazolam, six participants (21%) reported prescribed use only, and two participants reported a
combination of prescription and illicit sources. Seven participants (25%) had not used alprazolam in the
previous three months.

The most common form of illicit alprazolam was 2mg tablets – the strongest dose formulation available in
Australia. The cost of ‘street’ alprazolam doubled, rising from a mode of $5 (20 out of 35 participants who
reported a street price) per 2mg tab at baseline to $10 (reported by 4/12) at three month follow up and $10
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(reported by 22/31) at 12 month follow-up. Too few people reported purchase of lower strength tablets to
report meaningful estimates.
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Conclusions

Using a longitudinal study design with within subject analyses, we were able to examine the effect of a
change in the scheduling of alprazolam in a population of OST clients who report regular benzodiazepine
use. To the authors knowledge this is the first prospectively conducted cohort study examining the impact of
benzodiazepine up-scheduling. We found that alprazolam use reduced significantly in this population at three
months follow up which was maintained at 12 months follow up but not eliminated. Total benzodiazepine
consumption also reduced at 12 months compared to baseline. Furthermore, there was no evidence of
substitution with other drug classes, with patterns of cannabis, alcohol, opioid, stimulant and other
psychiatric medications (antidepressants, antipsychotic medications) remaining stable.

Following the change in scheduling the street price for 2mg alprazolam (the most commonly used strength
amongst this cohort) increased, consistent with a reduction in its availability. Monitoring of street prices in
larger surveillance studies such as the Illicit Drug Reporting System (Stafford & Burns, 2013) will further
inform about the effect of this change on broader populations of people who use drugs.

Similarly, there were few observable changes in a range of self-reported health outcomes, suggesting that
unintended harms (such as increased mental health or sleep problems) were not experienced by this group
as a result of the scheduling change and associated reduction in total benzodiazepine use. Indeed, this
study observed reductions in insomnia over time.

These findings are similar to a multicentre Australian cross-sectional study of the effects of a restriction in
government subsidies for the capsule formulation of temazepam in 2002 (Breen, Degenhardt, Bruno,
Roxburgh, & Jenkinson, 2004). This study also identified that few unintended harms were observed and
there was some reduction in capsule prescription and injection, though many did continue to source and use
this medication. However, injecting harms did continue to be observed until the product was removed from
the market in 2004 (Degenhardt et al., 2008). It will be important to examine the longer-term outcomes of this
scheduling change of alprazolam to determine if the medium-term benefits (reduced total benzodiazepine
use) are maintained.
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As alprazolam continues to be available, particularly from illicit sources for this cohort, it is unlikely that all of
the concerns relating to alprazolam use will be addressed by this recent scheduling change. It is worth noting
that a minority of participants continued to source alprazolam via prescription, despite the regulatory change
restricting prescription to OST clients. We do not know if prescribing doctors were compliant with the
regulations requiring them to seek authority prior to prescribing alprazolam to these participants, and there is
limited capacity to monitor or enforce the regulatory changes. Nevertheless, reduced access appeared to
follow the regulatory changes. Real-time prescription monitoring programs may provide another tool to
enforce regulatory change, but given the majority of alprazolam use in this sample was illicit (not from
people’s own prescriptions) prescription monitoring may only have an indirect effect by reducing the volume
of illicit alprazolam available.

Long-term effects on cognitive function have been well described with benzodiazepine use (Barker,
Greenwood, Jackson, & Crowe, 2004). It is possible that with some continuing benzodiazepine and other
drug use (and relatively high doses of diazepam equivalents at each time point) that we were not able to
detect the changes in cognitive and general function. How best to achieve abstinence or even stable
reduced doses of benzodiazepines remains an important and challenging clinical area in which further work
is sorely needed, particularly for an OST population (Lintzeris & Nielsen, 2010). Given the high rates of
benzodiazepine use among opioid dependent treatment populations internationally (Chen et al., 2011;
Heikman, Sundström, Pelander, & Ojanperä, 2016; Meiler et al., 2005; Park, Bohnert, Austin, Saitz, & Pizer,
2014), cognitive effects of benzodiazepines remain an issue of significant public health concern

There are some important limitations in interpreting these data. Firstly, the small sample size may restrict
power to detect both changes over time and predictors of change. Secondly, some recall bias amongst a
cognitively impaired sample of OST clients who use benzodiazepines is possible, though with careful use of
time-line follow back methods most participants were able to report their substance use in detail, and timeline follow back is a validated method of data collection amongst substance using populations (Hjorthøj,
Hjorthøj, & Nordentoft, 2012; Sacks, Drake, Williams, Banks, & Herrell, 2003; Sobell & Sobell, 1992).
Although self-report was not supplemented with objective measures such as urine drug screens, the latter
would also have been restricted to indicating recent use only without indicating frequency or volume of use.
Despite the small sample, clear changes were able to be observed. While small, this sample represents one
of the highest risk populations at which regulatory changes were targeted. Another potential limitation is the
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absence of a comparison group, and it is possible that some of the identified changes over time (such as
reduced total benzodiazepine use) may represent maturation cohort effects of remaining in long term OST
treatment – as suggested in previous OST studies (Brands et al., 2008). This study was restricted to OST
clients only; results are not necessarily representative of drug using populations in general. The authors are
aware of other cohorts (e.g. Illicit Drug Reporting System) monitoring changes among non-OST populations
and look forward to the findings of these studies with interest. The last limitation is the follow-up rate of 61%.
Those lost to follow-up did not differ from those followed up on most variables, but they did have significantly
longer benzodiazepine use histories. This raises concerns about whether patterns of drug use in followed up
participants was representative of the whole sample.

Strengths of the study include a prospective cohort design with a statistical analysis taking account of
missing data, detailed measures of substance use and well validated measures that may capture a range of
unintended harms from restriction of alprazolam. The population recruited are broadly representative of OST
patients in NSW more generally being on standard OST doses, mostly being male and prescribed
methadone, and representing an ageing OST cohort has had been identified in other data collection sources
(Australian Institute of Health and Welfare, 2014).

Twelve months after the scheduling change we were able to detect significant reductions in both alprazolam
use, and total benzodiazepine use amongst this high-risk population without observing unintended harms in
terms of measures of sleep, mental health or non-benzodiazepine substance use. Examining the effects
amongst other at risk populations, and over longer time periods is important further work.

Implications
Regulatory changes in pharmaceutical medications can impact upon the accessibility and patterns of use of
medications. This study indicates that the regulatory change of rescheduling alprazolam from S4 to S8 was
associated with reduced levels of alprazolam and total benzodiazepine use in a high-risk population of OST
clients.
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Table one. Participant demographics, physical and mental health at baseline, comparing those
followed up and not followed up at 12 months
A. Total
sample, n=57
Age, mean (SD)
Gender, n (%) male
Completed high school, n (%)
Employed at baseline, n (%)
Homeless at baseline, n (%)
Opioid substitution medication
type methadone, n (%)
Years regular benzodiazepine
use, median (range)

C .12 months not
followed up, n=22

p (B v C)

44 (8.7)
34 (60%)
19 (33%)
4 (7%)
5 (9%)
47 (82%)

B. Followed up
at 12 months,
n=35
44 (8.9)
21 (60%)
15 (43%)
3 (9%)
3 (9%)
28 (80%)

44 (8.7)
13 (59%)
4 (18%)
1 (4%)
2 (9%)
19 (86%)

0.9591
1.0002
0.0833
1.0003
1.0003
0.7252

15.5 (1-53)

8.5 (1-40)

24.5 (3-53)

U=185,
p=0.0024

1

ANOVA
chi-square test
3
Fischer’s exact test
4
Mann-Whitney test
2

1

Table two: Linear mixed model results for alprazolam and total benzodiazepine use over 3 time
points.

Dependent
variable

Model

Independent variables

Estimations

Model 1: Total 7
day alprazolam
load mg

Base

Timepoint

Baseline
3 months
12 months

14.9 (10.8-19.0)
8.3 (3.9-12.6)
6.3 (1.5-11.2)

0.007
0.001

Best fit

Timepoint + SF-36
physical component score1
+ insomnia2 + stress3

Baseline
3 months
12 months

15.1 (11.0-19.3)
8.7 (4.3-13.1)
6.1 (1.2-11.1)

0.009
0.001

Base

Timepoint

Baseline
3 months
12 months

14.1 (11.3-16.8)
8.6 (5.8-11.4)
7.9 (4.8-11.1)

<0.001
0.001

Best fit

Timepoint + site + SF-36
physical component score1
+ insomnia2

Baseline
3 months
12 months

13.7 (10.7-16.6)
8.5 (5.5-11.4)
7.1 (3.7-10.5)

0.001
0.001

Base

Timepoint

Baseline
3 months
12 months

222 (142-303)
212 (126-298)
157 (70-245)

0.857
0.044

Best fit

Timepoint + SF-36
physical component score1
+ insomnia2 + anxiety3

Baseline
3 months
12 months

225 (144-306)
223 (136-310)
151 (63-239)

0.972
0.028

Base

Timepoint

Baseline
3 months
12 months

18.8 (15.9-21.8)
17.0 (13.8-20.1)
14.9 (11.4-18.5)

0.274
0.040

Best fit

Timepoint + SF-36
physical component score1
+ insomnia2

Baseline
3 months
12 months

18.5 (15.5-21.4)
17.1 (13.9-20.2)
14.7 (11.1-18.3)

0.434
0.065

Model 2:
Alprazolam, days
of use in last 28

Model 3: Total 7
day all
benzodiazepine
load, diazepam
equivalent mg

Model 4: All
benzodiazepines,
days of use in
last 28

1

Measured using the SF-36v2 Health Survey
Measured using the Insomnia Severity Index
3
Measured using the short form version of the Depression Anxiety Stress Scales.
2

2

p

Table three: Changes in proportion and frequency of non-benzodiazepine substance use among 35
participants followed up at timepoints 2 and 3. Mean days of use is calculated using only those participants
who used at each timepoint.
Baseline Follow up 1 Follow up 2
p (McNemar)
(n=35)
(n=35)
(n=35)

Heroin

Pharmaceutical
opioids

Amphetamines

Cocaine

Cannabis

Alcohol

Antidepressants

Antipsychotics

Baseline vs
Follow up 2

Follow up 1 vs
Follow up 2

1.000

% used

17 (49)

14 (41)

14 (40)

0.375

Mean days of use
(SD)

9 (8)

9 (7)

9 (8)

-

% used

7 (20)

3 (9)

4 (11)

0.375

Mean days of use
(SD)

8 (10)

2 (2)

7 (9)

-

% used

12 (34)

11 (32)

11 (32)

1.000

Mean days of use
(SD)

6 (6)

6 (6)

4 (6)

-

% used

5 (14)

4 (12)

0 (0)

0.063

Mean days of use
(SD)

4 (2)

4 (6)

4 (4)

-

% used

21 (60)

18 (53)

21 (60)

1.000

Mean days of use
(SD)

17 (12)

17 (11)

19 (11)

-

% used

18 (51)

16 (48)

18 (51)

1.000

Mean days of use
(SD)

13 (10)

12 (10)

10 (10)

-

% used

11 (31)

11 (32)

11 (31)

1.000

Mean days of use
(SD)

20 (12)

19 (12)

25 (8)

-

% used

5 (14)

6 (18)

7 (21)

0.687

Mean days of use
(SD)

24 (7)

23 (7)

21 (13)

-

3

1.000

1.000

0.125

0.625

1.000

1.000

1.000

Table four: Changes in mean scores and proportion scoring below normal range of physical and mental
health markers among 35 participants followed up at waves 2 and 3.
Baseline
(n=35)

Follow up 1
(n=35)

Follow up 2
(n=35)

p
(repeated
measures
ANOVA)
0.117

Cognitive
impairment
score1

Mean (SD)

23.7 (3.3)

22.7 (3.5)

23.8 (3.6)

Proportion below
cutoff for normal
cognition (<26)

71%

79%

60%

Physical
component
score2

Mean (SD)

45.6 (9.5)

48.3 (10.1)

46.1 (10.5)

Proportion below
population mean
(<50.0)

69%

56%

60%

Mental
component
score2

Mean (SD)

32.0 (9.4)

34.2 (11.3)

34.6 (13.4)

Proportion below
population mean
(<50.0)

91%

91%

83%

Depression
score3

Mean (SD)

11.6 (5.9)

10.3 (6.1)

9.7 (6.2)

Proportion above
severe cutoff(≥11)

54%

52%

51%

Anxiety score3

Mean (SD)

8.9 (4.0)

8.7 (4.3)

7.3 (5.0)

Proportion above
severe cutoff (≥8)

69%

67%

43%

Mean (SD)

11.5 (4.6)

12.3 (4.8)

10.1 (5.0)

Proportion above
severe cutoff (≥13)

49%

51%

37%

Mean (SD)

14.9 (7.6)

15.3 (6.9)

11.8 (7.5)

Proportion above
clinically significant
cutoff (≥15)

51%

68%

37%

Stress score3

Insomnia
score4

1

0.234

0.434

0.291

0.200

0.108

<0.001

Measured using the Montreal Cognitive Assessment; scores above 25/30 indicate normal cognition
Measured using the SF-36v2 Health Survey; US population norms are 50.
3
Measured using the short form version of the Depression Anxiety Stress Scales; Cut-off scores out of 21 for severe or
very severe depression, anxiety and/or stress are 11+, 8+ and 13+ respectively.
4
Measured using the Insomnia Severity Index; a score of 15 or above indicates clinically significant insomnia.
2

4

